Immunohistochemical analysis of L1 cell adhesion molecule and high endothelial venules in breast cancer brain metastasis.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Brain Neoplasms
/ chemistry
Breast Neoplasms
/ pathology
Endothelial Cells
/ chemistry
Female
Humans
Immunohistochemistry
Middle Aged
Neural Cell Adhesion Molecule L1
/ analysis
Predictive Value of Tests
Retrospective Studies
Tumor Microenvironment
Venules
/ chemistry
Brain metastasis
Breast cancer
L1CAM
MECA-79
Microenvironment
Vascular co-option
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
27
03
2021
revised:
09
05
2021
accepted:
10
05
2021
pubmed:
23
5
2021
medline:
15
12
2021
entrez:
22
5
2021
Statut:
ppublish
Résumé
The vasculature is a crucial factor in tumor development. Vascular co-option achieved by the L1 cell adhesion molecule (L1CAM) and lymphocyte recruitment inside tumors by high endothelial venules (HEVs) are important prognostic factors in primary breast cancer. Their status in breast cancer brain metastasis is unknown. To explore the status of L1CAMs and HEVs in this tumor compartment. Thirty resected breast cancer brain metastases were immunohistochemically studied for L1CAM and MECA-79, an HEV marker. Clinicopathological factors were recorded. Age at brain metastasis diagnosis ranged from 37 to 80 years (median 55). The time to brain metastasis development after primary tumor diagnosis ranged from 12 to 187 months (median 57). Median overall survival after brain metastasis diagnosis was 29 months. None of the tumors expressed the factors studied. L1CAM and high endothelial venules are not found in breast cancer brain metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
The vasculature is a crucial factor in tumor development. Vascular co-option achieved by the L1 cell adhesion molecule (L1CAM) and lymphocyte recruitment inside tumors by high endothelial venules (HEVs) are important prognostic factors in primary breast cancer. Their status in breast cancer brain metastasis is unknown.
AIM OF THE STUDY
OBJECTIVE
To explore the status of L1CAMs and HEVs in this tumor compartment.
MATERIAL AND METHODS
METHODS
Thirty resected breast cancer brain metastases were immunohistochemically studied for L1CAM and MECA-79, an HEV marker. Clinicopathological factors were recorded.
RESULTS
RESULTS
Age at brain metastasis diagnosis ranged from 37 to 80 years (median 55). The time to brain metastasis development after primary tumor diagnosis ranged from 12 to 187 months (median 57). Median overall survival after brain metastasis diagnosis was 29 months. None of the tumors expressed the factors studied.
CONCLUSION
CONCLUSIONS
L1CAM and high endothelial venules are not found in breast cancer brain metastasis.
Identifiants
pubmed: 34022682
pii: S0344-0338(21)00145-X
doi: 10.1016/j.prp.2021.153484
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
L1CAM protein, human
0
Neural Cell Adhesion Molecule L1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
153484Informations de copyright
Copyright © 2021 Elsevier GmbH. All rights reserved.